Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James Aggen"'
Autor:
Catherine E. Gleason, Pablo D. Garcia, Ranya Odeh, Frances Hamkins-Indik, Daphne He, Meisam Nosrati, Gavin Situ, Roberta Sala, Bernard Levin, Li-Fen Liu, Evelyn W. Wang, Siegfried Leung, Breena Fraga, Andrew T. Bockus, Justin Shapiro, Nathan Dupper, Chinmay Bhatt, Kai Yang, Megan DeMart, Sammy Metobo, James Aggen, Peadar Cremin, Ramesh Bambal, Constantine Kreatsoulas, David J. Earp, Rajinder Singh
Publikováno v:
Cancer Research. 83:1560-1560
RB and E2F genes are frequently altered in cancer. Cyclin/Cdk (cyclin-dependent kinase) complexes regulate the activity of RB and E2F to drive cell cycle progression and ensure fidelity of DNA replication. A critical subset of their substrates (Rb, E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd0da7b3d05cfd0214fb1750100fd482
https://doi.org/10.1158/1538-7445.am2023-1560
https://doi.org/10.1158/1538-7445.am2023-1560
Autor:
Pablo D. Garcia, Catherine E. Gleason, Miles Membreno, Frances Hamkins-Indik, Gavin Situ, Bernard Levin, Evelyn W. Wang, Siegfried Leung, Breena Fraga, Andrew Bockus, James Aggen, David Spellmeyer, David J. Earp, Rajinder Singh
Publikováno v:
Cancer Research. 82:5379-5379
Inhibition of substrate binding to Cyclin A has been postulated to be synthetically lethal in retinoblastoma (Rb) mutated cancers (Chen et al 1999). While compounds that target the cyclin-associated kinases are approved for clinical use, attempts to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94cc85dfbb00c536ea96cf5d178016ec
https://doi.org/10.1158/1538-7445.am2022-5379
https://doi.org/10.1158/1538-7445.am2022-5379
Autor:
Tomoko Ozawa, William A. Weiss, Qi-Wen Fan, Edward G. Lorenzana, James Aggen, Kevan M. Shokat, Xujun Luo, Ozlem Aksoy, Mallika Singh, Douglas R. Wassarman, Nicholas Butowski, Robin Lea, Z. H. An, Jaqueline A.M. Smith, David R. Raleigh
Publikováno v:
Neuro Oncol
Activation of phosphatidylinositol 3-kinase (PI3K)/PTEN pathway and oncogenic signaling via the mechanistic target of rapamycin (mTOR) occur in a majority of high-grade glial brain tumors. Allosteric mTOR inhibitors, such as rapamycin and other rapal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::557dddab96fdef5fe6d5336f0070b240
https://doi.org/10.1093/neuonc/noz175.284
https://doi.org/10.1093/neuonc/noz175.284